Truist Securities Maintains Buy on Arcus Biosciences, Lowers Price Target to $40
Benzinga Newsdesk 1 day ago
Analyst RatingsNewsPrice Target
Truist Securities analyst Supawat Thongthip maintains Arcus Biosciences (NYSE:RCUS) with a Buy and lowers the price target from $41 to $40.
Truist Securities analyst Supawat Thongthip maintains Arcus Biosciences (NYSE:RCUS) with a Buy and lowers the price target from $41 to $40.